Brief: Xspray Says Dasynoc™ May Mitigate Increased Mortality In CML Treatment
26/10/2023 14:39
Oct 26 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST :
* XSPRAY PUBLICATION DEMONSTRATES HIGH CONCOMITANT PPI AND
TKI USE
IN CML RESULTING IN RISK OF INCREASED MORTALITY WHICH MAY BE
MITIGATED BY DASYNOC™
Source text for Eikon: ID:nMFN8ChzmT
Further company coverage: XSPRAY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003